Loading...
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Heinrich, Michael C. Jones, Robin L. George, Suzanne Gelderblom, Hans Schöffski, Patrick von Mehren, Margaret Zalcberg, John R. Kang, Yoon-Koo Razak, Albiruni Abdul Trent, Jonathan
Heinrich, Michael C.
Jones, Robin L.
George, Suzanne
Gelderblom, Hans
Schöffski, Patrick
von Mehren, Margaret
Zalcberg, John R.
Kang, Yoon-Koo
Razak, Albiruni Abdul
Trent, Jonathan
Citations
Altmetric:
Genre
Journal article
Date
2024-01-05
Advisor
Committee member
Department
Permanent link to this record
Collections
Files
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1038/s41591-023-02734-5
Abstract
INTRIGUE was an open-label, phase 3 study in adult patients with advanced gastrointestinal stromal tumor who had disease progression on or intolerance to imatinib and who were randomized to once-daily ripretinib 150 mg or sunitinib 50 mg. In the primary analysis, progression-free survival (PFS) with ripretinib was not superior to sunitinib. In clinical and nonclinical studies, ripretinib and sunitinib have demonstrated differential activity based on the exon location of KIT mutations. Therefore, we hypothesized that mutational analysis using circulating tumor DNA (ctDNA) might provide further insight. In this exploratory analysis (N = 362), baseline peripheral whole blood was analyzed by a 74-gene ctDNA next-generation sequencing–based assay. ctDNA was detected in 280/362 (77%) samples with KIT mutations in 213/362 patients (59%). Imatinib-resistant mutations were found in the KIT ATP-binding pocket (exons 13/14) and activation loop (exons 17/18). Mutational subgroup assessment showed 2 mutually exclusive populations with differential treatment effects. Patients with only KIT exon 11 + 13/14 mutations (ripretinib, n = 21; sunitinib, n = 20) had better PFS with sunitinib versus ripretinib (median, 15.0 versus 4.0 months). Patients with only KIT exon 11 + 17/18 mutations (ripretinib, n = 27; sunitinib, n = 25) had better PFS with ripretinib versus sunitinib (median, 14.2 versus 1.5 months). The results of this exploratory analysis suggest ctDNA sequencing may improve the prediction of the efficacy of single-drug therapies and support further evaluation of ripretinib in patients with KIT exon 11 + 17/18 mutations. ClinicalTrials.gov identifier: NCT03673501.
Description
Citation
Heinrich, M.C., Jones, R.L., George, S. et al. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med 30, 498–506 (2024). https://doi.org/10.1038/s41591-023-02734-5
Citation to related work
Springer Science and Business Media
Has part
Nature Medicine, Vol. 30, Iss. 2
ADA compliance
Embedded videos
License
Attribution CC BY